Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Ruiyuan Cao and Wu Zhong.
Connection Strength

2.708
  1. Anti-SARS-CoV-2 Potential of Artemisinins In Vitro. ACS Infect Dis. 2020 09 11; 6(9):2524-2531.
    View in: PubMed
    Score: 0.898
  2. Sera proteomic features of active and recovered COVID-19 patients: potential diagnostic and prognostic biomarkers. Signal Transduct Target Ther. 2021 06 03; 6(1):216.
    View in: PubMed
    Score: 0.237
  3. Pathological features of COVID-19-associated liver injury-a preliminary proteomics report based on clinical samples. Signal Transduct Target Ther. 2021 01 08; 6(1):9.
    View in: PubMed
    Score: 0.231
  4. Pathological features of COVID-19-associated lung injury: a preliminary proteomics report based on clinical samples. Signal Transduct Target Ther. 2020 10 15; 5(1):240.
    View in: PubMed
    Score: 0.227
  5. Comparative Antiviral Efficacy of Viral Protease Inhibitors against the Novel SARS-CoV-2 In Vitro. Virol Sin. 2020 Dec; 35(6):776-784.
    View in: PubMed
    Score: 0.226
  6. Design, synthesis and pharmacological evaluation of a novel mTOR-targeted anti-EV71 agent. Eur J Med Chem. 2019 Aug 01; 175:172-186.
    View in: PubMed
    Score: 0.205
  7. Design and synthesis of piperidine derivatives as novel human heat shock protein 70 inhibitors for the treatment of drug-resistant tumors. Eur J Med Chem. 2015 Jun 05; 97:19-31.
    View in: PubMed
    Score: 0.155
  8. Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza. EBioMedicine. 2020 Dec; 62:103125.
    View in: PubMed
    Score: 0.057
  9. Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series. Crit Care. 2020 09 25; 24(1):578.
    View in: PubMed
    Score: 0.057
  10. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell Discov. 2020; 6:28.
    View in: PubMed
    Score: 0.055
  11. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020; 6:16.
    View in: PubMed
    Score: 0.055
  12. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing). 2020 Oct; 6(10):1192-1198.
    View in: PubMed
    Score: 0.055
  13. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 03; 30(3):269-271.
    View in: PubMed
    Score: 0.054
  14. MAVS O-GlcNAcylation Is Essential for Host Antiviral Immunity against Lethal RNA Viruses. Cell Rep. 2019 08 27; 28(9):2386-2396.e5.
    View in: PubMed
    Score: 0.052
  15. De Novo Design of a-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. J Med Chem. 2018 10 11; 61(19):8734-8745.
    View in: PubMed
    Score: 0.049
  16. Design, synthesis and in vitro anti-Zika virus evaluation of novel Sinefungin derivatives. Eur J Med Chem. 2018 Sep 05; 157:994-1004.
    View in: PubMed
    Score: 0.049
  17. A comprehensive study on cellular RNA editing activity in response to infections with different subtypes of influenza a viruses. BMC Genomics. 2018 01 19; 19(Suppl 1):925.
    View in: PubMed
    Score: 0.047
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.